← Back to Search

Flavonoid

Fisetin for Chronic Kidney Disease

Phase 2
Waitlist Available
Led By LaTonya J Hickson, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial will study the effects of fisetin on different aspects of health in people with chronic kidney disease.

Eligible Conditions
  • Chronic Kidney Disease
  • Diabetic Kidney Disease
  • Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in inflammatory markers including C-reactive protein
Effect on Mesenchymal stem cell function including cell migration
Secondary outcome measures
Effect on measures of Frailty including Fried Criteria
Kidney function including estimated glomerular filtration rate
Kidney function including urine protein excretion rate
+1 more

Side effects data

From 2022 Phase 2 trial • 55 Patients • NCT04771611
7%
Rash
7%
hyperhidrosis
7%
Chest pain
7%
Diarrhea
7%
Sinusitis
7%
Infectious Rash
7%
Back Pain
7%
Headache
7%
Worsening Headache
7%
Dyspnea
7%
sore throat
3%
hypertension
3%
tachycardia
3%
amnesia
3%
asthma with exacerbation
3%
Anosmia
3%
migraine
3%
conjunctivitis
3%
rhinitis
3%
flu like symptoms
3%
Otitis media
3%
vertigo
3%
edema, hand, bilateral
3%
bacterial vaginosis
3%
ear pain, left
3%
cough
3%
Upper Respiratory Infection
3%
Epistaxis
3%
flatulence
3%
shortness of breath
3%
arthoplasty
3%
ageusia
3%
change in smell
3%
vomiting
3%
fatigue
3%
Colic Renal
3%
Nephrolithiasis Calcium Oxalate
3%
sneezing
3%
thrush
3%
right shoulder arthroscopy, rotator cuff, repair
3%
watering eyes (epiphora)
3%
Systolic murmur
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment Group
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TreatmentExperimental Treatment1 Intervention
Fisetin 20 mg/kg/day, orally for 2 consecutive days
Group II: PlaceboPlacebo Group1 Intervention
Placebo capsules orally for 2 consecutive days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fisetin
2016
Completed Phase 2
~170

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,208 Previous Clinical Trials
3,767,020 Total Patients Enrolled
LaTonya J Hickson, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
32 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When might we expect to see Fisetin hit store shelves?

"Fisetin is still being studied in Phase 2 clinical trials, so there is limited data supporting its safety. It received a score of 2."

Answered by AI

Are individuals under the age of 20 able to enroll in this experiment?

"To participate in this trial, applicants must be between 40-80 years old. Out of the 2,889 total clinical trials, 257 are for patients under 18 and 1632 are for seniors aged 65 and up."

Answered by AI

Are there any more positions available for volunteers in this experiment?

"Yes, this trial is looking for more participants and was last updated on 9/21/2022 according to the clinicaltrials.gov website."

Answered by AI

How many people are currently enrolled in this clinical trial?

"That is correct, the listing on clinicaltrials.gov indicates that this study is still opening its doors to patients. The trial was created on 1/2/2018 and updated as recently as 9/21/2022. So far, 30 people have been admitted across 1 site."

Answered by AI

What are the benefits that researchers hope to achieve through this clinical trial?

"The main goal of this study, which will last for two weeks, is to see how effective the treatment is at reducing inflammation. Secondary objectives include assessing the safety of the medication and its impact on kidney function."

Answered by AI

How can I become a part of this experiment?

"The ideal participants for this clinical trial are people with diabetic nephropathies that are between 40 and 80 years old. Out of the total 30 desired candidates, how many patients will you be able to screen?"

Answered by AI

Who else is applying?

What state do they live in?
California
How old are they?
65+
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease
LaTonya J. Hickson 2018. "Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03325322.
~6 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top